Clinuvel Pharmaceuticals (CUV)

Download button icon Download

Clinuvel Pharmaceuticals (CUV): Signals

No data currently available.

data-ad-format="auto">

Explore Compare Share

TECHNICAL ANALYSIS SUMMARY

Clinuvel Pharmaceuticals (CUV.AX)


Indicator:

TRIANGULAR MOVING AVERAGE


Last Signal:

BULLISH


Trading: BUY @ $17.98
Signal Strength: STRONG
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.


Clinuvel Pharmaceuticals (ASX:CUV) currently has a confirmed uptrend. Recent trading has caused the TMA 15 day average to exceed the closing price confirming the short term trend following indicator. Currently, the return on TMA15 is 9.6%.



A triangular moving average can be calculated using various input data such as prices volume or another technical indicator.

Calculation: Triangular Moving Average (TMA):
1) SMA: n period sum / n;
2) TMA = (n SMA period sum) / N;


PROFILE: Clinuvel Pharmaceuticals (CUV.AX)


Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |

About Clinuvel Pharmaceuticals (ASX:CUV):

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.

Top 10:

Triangular Moving Average

Download button icon Download
Company Close Change (%) Volume Value Signal
RAP Resapp Health 0.12 9.5 648,223 7.5 BULLISH CROSSOVER
SYR Syrah Resources 1.81 8.1 2,657,646 6.4 BULLISH CROSSOVER
LAU Lindsay Australia 0.38 7.1 78 1.9 BULLISH CROSSOVER
NTC Netcomm 0.73 6.6 269,340 1.5 BULLISH CROSSOVER
HFR Highfield Resources 0.68 4.6 190,412 1.6 BULLISH CROSSOVER
NUF Nufarm 5.99 4.5 2,246,031 1 BULLISH CROSSOVER
NEA Nearmap 1.58 4.3 958,935 1.2 BULLISH CROSSOVER
PRU Perseus Mining 0.38 4.2 2,218,608 2.2 BULLISH CROSSOVER
SDF Steadfast 2.8 4.1 2,306,708 0.9 BULLISH CROSSOVER
GWA GWA 2.77 4.1 536,580 2.9 BULLISH CROSSOVER
back to top